Last $53.04 USD
Change Today +0.12 / 0.23%
Volume 762.7K
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 10:31 AM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

710 Medtronic Parkway

Minneapolis, MN 55432-5604

United States

Phone: 763-514-4000

Fax: 763-514-4879

www.medtronic.com

les. Customers: The primary medical specialists who use Spinal products are spinal surgeons, orthopedic surgeons, neurosurgeons, and interventional radiologists. Competition: Competitors in this business include DePuy Spine, Inc., Synthes, Inc., Stryker Corporation, NuVasive, Inc., Globus Medical, Inc., Zimmer, Inc., Alphatec Spine, Inc., Orthofix International N.V., Biomet, Inc. NEUROMODULATION The company’s Neuromodulation business develops, manufactures, and markets medical devices for the treatment of pain, movement disorders, psychological disorders, and urological and gastroenterological disorders. The following are the principal products offered by its Neuromodulation business: Neurostimulators for Chronic Pain: The company has a portfolio of neurostimulation systems, including rechargeable and non-rechargeable devices and a selection of leads used to treat chronic back and leg pain. Its portfolio of products includes the RestoreSensor (rechargeable), with proprietary AdaptiveStim technology, as well as the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. Implantable Drug Delivery Systems: The SynchroMed II Programmable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke. Deep Brain Stimulation (DBS) Systems: DBS uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver carefully controlled electrical stimulation to precisely targeted areas in the brain. It works by electrically stimulating specific structures that control movement and muscle function. DBS is used to treat the symptoms of movement disorders such as Parkinson’s disease, epilepsy (certain countries outside the U.S. only), essential tremor, and dystonia, as well as psychiatric disorders such as obsessive-compulsive disorder. Its family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). Urology, Fecal, and Gastroenterology Devices: The company’s therapeutic portfolio for urology and gastroenterology includes the InterStim Therapy System, which treats the symptoms of overactive bladder, urinary retention, and chronic fecal incontinence, and the Enterra Therapy System for the treatment of chronic nausea and vomiting caused by gastroparesis of diabetic or idiopathic origin for drug refractory patients. Customers: The primary medical specialists who use pain management and movement disorder products are neurosurgeons, neurologists, pain management specialists, anesthesiologists, physiatrists, and orthopedic spine surgeons. The primary medical specialists who use gastroenterology and urology products are urologists, urogynecologists, gastroenterologists, and colorectal surgeons. Competition: The company’s primary competitors in this business are Boston Scientific and St. Jude. It also competes with Urologix, Inc. and Allergan. Diabetes The company’s Diabetes business develops, manufactures, and markets advanced, integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring systems, and therapy management software. The following are the principal products offered by Diabetes business: Integrated Diabetes Management Solutions: The company offers integrated insulin pump and continuous glucose monitoring (CGM) system in the U.S. Outside the U.S., it offers Paradigm Veo System, an integrated system that includes a Low Glucose Suspend feature that automatically suspends insulin delivery when glucose levels become too low. In the U.S., the company offers the Paradigm Revel System, which incorporates new CGM features including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events. Professional CGM: The company offers physicians a Prof

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $53.04 USD +0.12

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $36.99 USD -0.52
Allergan Inc/United States $101.06 USD -0.43
Baxter International Inc $70.51 USD -0.37
Covidien PLC $65.37 USD -0.57
Stryker Corp $67.77 USD +0.10
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 15.7x
Price/Sales 3.2x
Price/Book 2.9x
Price/Cash Flow 14.1x
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.